Jun 2026 (Q2 FY26) — Aug 6, 2026
Ironwood Pharmaceuticals Q2 FY26 — Strong Linzess Performance and Apraglutide Advancement
Read the full callIronwood Pharmaceuticals (IRWD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Ironwood Pharmaceuticals earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 113 | +32.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 70.2 | +17.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 51.3 | +117.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$3.56 +1.71% · +$0.06
Performance +149.0% 1Y
1Y: $1.43 on 17 Oct 2025 → $3.56. High $5.39 (22 Jan 2026), low $1.43 (17 Oct 2025).
- Previous close
- $3.5
- 52-week range
- $1.5 – $5.39
- One year
- +131.17%
Overview
- Symbol
- IRWD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Ironwood Pharmaceuticals earnings calls (IRWD)
Financials
What the filings say
Net profit, year on year: +117% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 92 | 91 | 41 | 85 | 122 | 48 | 107 | 113 |
| Expenses | 66 | 59 | 70 | 40 | 47 | 41 | 34 | 34 |
| Operating profit | 26 | 31 | -29 | 45 | 75 | 7 | 73 | 79 |
| Operating margin | 28.0% | 34.8% | −70.8% | 53.2% | 61.8% | 14.3% | 68.1% | 70.2% |
| Other income | -8 | -7 | -7 | -7 | -7 | -6 | -7 | -6 |
| Interest | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 7 |
| Profit before tax | 17 | 24 | -36 | 38 | 68 | 0 | 65 | 74 |
| Tax rate | 79.0% | 90.6% | −3.1% | 37.6% | 41.1% | 600.2% | 37.4% | 30.4% |
| Net profit | 4 | 2 | -37 | 24 | 40 | -2 | 41 | 51 |
| EPS ($ per share) | 0.02 | 0.01 | -0.23 | 0.15 | 0.25 | -0.01 | 0.25 | 0.31 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,591 | -1,572 | -1,466 | -938 | -696 | -1,699 | -1,698 | -1,674 |
| Total liabilities | 528 | 496 | 497 | 521 | 448 | 817 | 652 | 659 |
| Fixed assets | 8 | 12 | 9 | 8 | 6 | 6 | 4 | 3 |
| Total assets | 332 | 403 | 559 | 1,127 | 1,101 | 471 | 351 | 397 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -71 | 11 | 169 | 262 | 274 | 183 | 104 | 127 |
| Cash from investing | 89 | -11 | -2 | -0 | -0 | -1,026 | -0 | -0 |
| Cash from financing | 30 | -1 | 19 | -5 | -238 | 277 | -107 | 0 |
| Net cash flow | 48 | -2 | 186 | 257 | 36 | -566 | -4 | 127 |
| Capital expenditure | -0 | -7 | -2 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | -71 | 4 | 167 | 262 | 274 | 183 | 103 | 127 |
Insider filings
37 filings between Nov 17, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$22.62M
18 sales by 8 insiders
17% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 19
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| DENNER ALEXANDER J | — | $20.53M | Mar 17, 2026 |
| Silver Ronald | — | $831.2K | Jul 7, 2026 |
| MCCOURT Thomas A | — | $739.9K | Feb 24, 2026 |
| John Minardo | — | $136.2K | Feb 24, 2026 |
| Shetzline Michael | — | $121.6K | Feb 24, 2026 |
| Gaskins Tammi L | — | $100.3K | Feb 24, 2026 |
| Martini Gregory S. | — | $81.9K | Feb 24, 2026 |
| McHugh Julie | — | $80.5K | Jun 16, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | DENNER ALEXANDER J Director | Award | 3,694 | $0 |
| Jul 20, 2026 | Silber Jeffrey SVP, CMO, Head-Res&Drug | Award | 137,036 | $0 |
| Jul 7, 2026 | Silver Ronald PFO & PAO | Sale 10b5-1 plan | 127,890 | $578.1K |
| Jun 16, 2026 | McHugh Julie Director | Award 10b5-1 plan | 63,481 | $0 |
| Jun 16, 2026 | McHugh Julie Director | Sale 10b5-1 plan | 21,571 | $80.5K |
| Jun 16, 2026 | DENNER ALEXANDER J Director | Award | 63,481 | $0 |
| Jun 16, 2026 | Duane Jon R Director | Award | 63,481 | $0 |
| Jun 16, 2026 | Currie Mark G Director | Award | 63,481 | $0 |
| Jun 16, 2026 | Kessler Marla L Director | Award | 63,481 | $0 |
| Jun 16, 2026 | Shepard Jay Director | Award | 63,481 | $0 |
| Jun 16, 2026 | Moukheibir Catherine Director | Award | 63,481 | $0 |
| Jun 15, 2026 | DENNER ALEXANDER J Director | Award | 4,065 | $0 |
| May 19, 2026 | Silver Ronald PFO & PAO | Award | 25,000 | $0 |
| Mar 17, 2026 | DENNER ALEXANDER J Director | Sale | 6,725,000 | $20.51M |
| Mar 17, 2026 | DENNER ALEXANDER J Director | Sale | 5,800 | $19.2K |
| Mar 13, 2026 | DENNER ALEXANDER J Director | Award | 4,451 | $0 |
| Mar 10, 2026 | Martini Gregory S. Chief Financial Officer | Award | 136,612 | $0 |
| Mar 10, 2026 | John Minardo Chief Legal Officer | Award | 136,612 | $0 |
| Mar 10, 2026 | Silver Ronald Principal Accounting Officer | Award | 163,934 | $0 |
| Mar 10, 2026 | Shetzline Michael SVP, CMO, Head-Res&Drug | Award | 136,612 | $0 |
| Mar 10, 2026 | Gaskins Tammi L Chief Commercial Officer | Award | 136,612 | $0 |
| Mar 10, 2026 | MCCOURT Thomas A Chief Executive Officer | Award | 409,836 | $0 |
| Feb 24, 2026 | Shetzline Michael SVP, CMO, Head-Res&Drug | Sale | 17,012 | $62.3K |
| Feb 24, 2026 | Gaskins Tammi L Chief Commercial Officer | Sale | 11,239 | $41.1K |
| Feb 24, 2026 | John Minardo Chief Legal Officer | Sale | 19,053 | $69.7K |
| Feb 24, 2026 | MCCOURT Thomas A Chief Executive Officer | Sale | 103,526 | $378.9K |
| Feb 24, 2026 | Martini Gregory S. Chief Financial Officer | Sale | 11,457 | $41.9K |
| Feb 24, 2026 | Silver Ronald Principal Accounting Officer | Sale | 12,621 | $46.2K |
| Feb 23, 2026 | Silver Ronald Principal Accounting Officer | Sale | 11,552 | $44.0K |
| Feb 23, 2026 | MCCOURT Thomas A Chief Executive Officer | Sale | 94,757 | $361.0K |
| Feb 23, 2026 | Gaskins Tammi L Chief Commercial Officer | Sale | 10,287 | $39.2K |
| Feb 23, 2026 | Shetzline Michael SVP, CMO, Head-Res&Drug | Sale | 15,570 | $59.3K |
| Feb 23, 2026 | John Minardo Chief Legal Officer | Sale | 17,439 | $66.4K |
| Feb 23, 2026 | Martini Gregory S. Chief Financial Officer | Sale | 10,487 | $40.0K |
| Jan 5, 2026 | Silver Ronald Principal Accounting Officer | Sale 10b5-1 plan | 35,416 | $162.9K |
| Dec 15, 2025 | DENNER ALEXANDER J Director | Award | 4,178 | $0 |
| Nov 17, 2025 | Gaskins Tammi L Chief Commercial Officer | Sale | 6,016 | $20.0K |
| Sep 15, 2025 | DENNER ALEXANDER J Director | Award | 11,718 | $0 |
| Aug 11, 2025 | Silver Ronald Principal Accounting Officer | Sale | 2,846 | $2.4K |
| Aug 11, 2025 | John Minardo Chief Legal Officer | Sale | 7,754 | $6.5K |
| Aug 11, 2025 | Gaskins Tammi L Chief Commercial Officer | Sale | 1,316 | $1.1K |
| Aug 11, 2025 | Martini Gregory S. Chief Financial Officer | Sale | 1,265 | $1.1K |
| Jun 13, 2025 | DENNER ALEXANDER J Director | Award | 24,193 | $0 |
| Jun 10, 2025 | Dreyfus Andrew Director | Award | 45,000 | $0 |
| Jun 10, 2025 | McHugh Julie Director | Award | 45,000 | $0 |
| Jun 10, 2025 | Currie Mark G Director | Award | 45,000 | $0 |
| Jun 10, 2025 | Duane Jon R Director | Award | 45,000 | $0 |
| Jun 10, 2025 | Moukheibir Catherine Director | Award | 45,000 | $0 |
| Jun 10, 2025 | Shepard Jay Director | Award | 45,000 | $0 |
| Jun 10, 2025 | Kessler Marla L Director | Award | 45,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for IRONWOOD PHARMACEUTICALS INC
Free account. Everything above stays public.
Write why you follow IRONWOOD PHARMACEUTICALS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading